This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis Of The Leading Generic Players In 2013

List of Figures

Figure 1: Generics Manufacturing Landscape Assessment – FY2012 Corporate Revenue Growth vs. Operating Margin 20Figure 2: Generics Manufacturing Landscape Assessment – FY2012 Generics Sales Growth vs. Operating Margin 21Figure 3: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Revenue 27Figure 4: FY2012 Leading Generic Pharmaceutical Companies by YTY Revenue Growth 31Figure 5: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Income ($m) 35Figure 6: FY2012 Leading Generic Pharmaceutical Companies by YTY Operating Income Growth 38Figure 7: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Margin 42Figure 8: Top 30 Generic Pharmaceutical Landscape Assessment – FY2012 SG&A Expense vs. Operating Expense as a Percentage of Revenue 44Figure 9: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending ($m) 45Figure 10: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue 50Figure 11: FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue, YTY Change 53Figure 12: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Expense as a Percentage of Revenue 57Figure 13: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Debt-to-Assets Ratio 65Figure 14: FY 2011 and FY2012, Leading Generic Pharmaceutical Companies by Cash Ratio 68Figure 15: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by ROI 71Figure 16: Sun Pharmaceuticals: SWOT Analysis 73Figure 17: Sandoz: SWOT Analysis 76Figure 18: Pharmstandard: SWOT Analysis 79Figure 19: Teva Pharmaceuticals: SWOT Analysis 82Figure 20: Teva Generics Sales in US vs. Rest-of-World (ROW)1, 2009–2012 85Figure 21: Actavis: SWOT Analysis 87Figure 22: Mylan: SWOT Analysis 90Figure 23: Ranbaxy: SWOT Analysis 93Figure 24: Dr. Reddy's: SWOT Analysis 94Figure 25: Covidien: SWOT Analysis 95Figure 26: Hospira: SWOT Analysis 96

Companies Mentioned

Sun Pharmaceuticals: The Benchmark LeaderSandoz PharmstandardTeva PharmaceuticalsActavis Mylan Ranbaxy Dr. Reddy's Covidien Hospira

To order this report: Generic_Drug Industry: PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

__________________________Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.86 +139.55 0.82%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,536.6280 -12.5980 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs